165 related articles for article (PubMed ID: 36914051)
21. Cerebrovascular disease in suspected non-Alzheimer's pathophysiology and cognitive decline over time.
Saridin FN; Chew KA; Reilhac A; Gyanwali B; Villaraza SG; Tanaka T; Scheltens P; van der Flier WM; Chen CLH; Hilal S
Eur J Neurol; 2022 Jul; 29(7):1922-1929. PubMed ID: 35340085
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
[TBL] [Abstract][Full Text] [Related]
23. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
[TBL] [Abstract][Full Text] [Related]
24. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism.
Benvenutto A; Giusiano B; Koric L; Gueriot C; Didic M; Felician O; Guye M; Guedj E; Ceccaldi M
J Alzheimers Dis; 2018; 65(4):1147-1157. PubMed ID: 30124446
[TBL] [Abstract][Full Text] [Related]
25. Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [
Chiaravalloti A; Barbagallo G; Martorana A; Castellano AE; Ursini F; Schillaci O
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1796-1805. PubMed ID: 31201430
[TBL] [Abstract][Full Text] [Related]
26. Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type.
Lagarde J; Olivieri P; Tonietto M; Gervais P; Comtat C; Caillé F; Bottlaender M; Sarazin M
Transl Psychiatry; 2021 Sep; 11(1):498. PubMed ID: 34588422
[TBL] [Abstract][Full Text] [Related]
27. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.
Wirth M; Villeneuve S; Haase CM; Madison CM; Oh H; Landau SM; Rabinovici GD; Jagust WJ
JAMA Neurol; 2013 Dec; 70(12):1512-9. PubMed ID: 24166579
[TBL] [Abstract][Full Text] [Related]
28. Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers.
Montembeault M; Brambati SM; Lamari F; Michon A; Samri D; Epelbaum S; Lacomblez L; Lehéricy S; Habert MO; Dubois B; Kas A; Migliaccio R
Neuroimage Clin; 2018; 20():1018-1025. PubMed ID: 30340200
[TBL] [Abstract][Full Text] [Related]
29. FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type.
Madhavan A; Whitwell JL; Weigand SD; Duffy JR; Strand EA; Machulda MM; Tosakulwong N; Senjem ML; Gunter JL; Lowe VJ; Petersen RC; Jack CR; Josephs KA
PLoS One; 2013; 8(4):e62471. PubMed ID: 23626825
[TBL] [Abstract][Full Text] [Related]
30. Pathological drivers of neurodegeneration in suspected non-Alzheimer's disease pathophysiology.
Wisse LEM; de Flores R; Xie L; Das SR; McMillan CT; Trojanowski JQ; Grossman M; Lee EB; Irwin D; Yushkevich PA; Wolk DA;
Alzheimers Res Ther; 2021 May; 13(1):100. PubMed ID: 33990226
[TBL] [Abstract][Full Text] [Related]
31. Cerebral amyloid accumulation is associated with distinct structural and functional alterations in the brain of depressed elders with mild cognitive impairment.
Hyung WSW; Kang J; Kim J; Lee S; Youn H; Ham BJ; Han C; Suh S; Han CE; Jeong HG
J Affect Disord; 2021 Feb; 281():459-466. PubMed ID: 33360748
[TBL] [Abstract][Full Text] [Related]
32. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
33. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
34. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease.
Chételat G; Desgranges B; Landeau B; Mézenge F; Poline JB; de la Sayette V; Viader F; Eustache F; Baron JC
Brain; 2008 Jan; 131(Pt 1):60-71. PubMed ID: 18063588
[TBL] [Abstract][Full Text] [Related]
35. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
36. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.
Rabinovici GD; Furst AJ; Alkalay A; Racine CA; O'Neil JP; Janabi M; Baker SL; Agarwal N; Bonasera SJ; Mormino EC; Weiner MW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ
Brain; 2010 Feb; 133(Pt 2):512-28. PubMed ID: 20080878
[TBL] [Abstract][Full Text] [Related]
37. No Association of Lower Hippocampal Volume With Alzheimer's Disease Pathology in Late-Life Depression.
De Winter FL; Emsell L; Bouckaert F; Claes L; Jain S; Farrar G; Billiet T; Evers S; Van den Stock J; Sienaert P; Obbels J; Sunaert S; Adamczuk K; Vandenberghe R; Van Laere K; Vandenbulcke M
Am J Psychiatry; 2017 Mar; 174(3):237-245. PubMed ID: 27539488
[TBL] [Abstract][Full Text] [Related]
38. Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia.
Mosconi L; Andrews RD; Matthews DC
J Alzheimers Dis; 2013; 35(3):509-24. PubMed ID: 23478305
[TBL] [Abstract][Full Text] [Related]
39. Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects.
Araque Caballero MÁ; Brendel M; Delker A; Ren J; Rominger A; Bartenstein P; Dichgans M; Weiner MW; Ewers M;
Neurobiol Aging; 2015 Nov; 36(11):2913-2924. PubMed ID: 26476234
[TBL] [Abstract][Full Text] [Related]
40. Widespread reductions in gray matter volume in depression.
Grieve SM; Korgaonkar MS; Koslow SH; Gordon E; Williams LM
Neuroimage Clin; 2013; 3():332-9. PubMed ID: 24273717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
